Long-term evaluation of triple nucleoside therapy administered from primary HIV-1 infection

AIDS

Volumn 13, Issue 10, 1999, Pages 1213-1220

  Poggi, Cécile ^a   Profizi, Nérina ^a   Djediouane, Abdelaziz ^a   Chollet, Lionel ^a   Hittinger, Gilles ^a   Lafeuillade, Alain ^a,b  

^a GENERAL HOSPITAL   (France)

^b Hopital Chalucet Toulon   (France)

Author keywords

Combination therapy; Cytokines; Eradication; HIV 1; Lymph nodes; Primary infection; Viral load

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DIDANOSINE; GAMMA INTERFERON; INTERLEUKIN 2; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNOBLOTTING; LYMPH NODE BIOPSY; MALE; MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROVIRUS; T LYMPHOCYTE SUBPOPULATION; VIRUS GENE; VIRUS REPLICATION;

ADULT; BLOTTING, WESTERN; CYTOKINES; DNA, VIRAL; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPH NODES; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; T-LYMPHOCYTE SUBSETS; VIRAL LOAD; VIRUS REPLICATION;

EID: 0032811568     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199907090-00010     Document Type: Article

References (30)

1. 1. Kinloch-de Loës S, Hirschel BJ, Hoen B, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995, 333:408-413.
2. 2. Kinloch-de Loës S, Perrin L. Therapeutic interventions in primary HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 10(Suppl. 1):S69-76.
3. 3. Lafeuillade A, Poggi C, Tamalet C, et al. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection. J Infect Dis 1997, 175:1051-1055.
4. 4. Hoen B, Harzic M, Dumon B et al. Efficacy of zidovudine, lamivudine and ritonavir combination in patients with symptomatic primary HIV-1 infection: the ANRS 053/53B trial. Can eradication be obtained? Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, January-February 1998 [abstract 524].
5. 5. Girard PM, Mariot P, Schneider V et al. Evaluation of 12-month triple nucleoside analogue therapy in 12 patients with primary HIV infection. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, January-February 1998 [abstract 581].
6. 6. Vila J, Nugier F, Bargués G et al. Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide. Lancet 1997, 350:635-6.
7. 7. St Clair MH, Pennington KN, Rooney J, Barry DW. In vitro comparison of selected triple-drug combinations for suppression of HIV-1 replication: the Inter-company Collaboration Protocol. J Acquir Immune Defic Syndr and Hum Retrovirol 1995, 10(Suppl. 2):S83-S91.
8. 8. Barin F, Courouce AM, Pillonel J, Buzely L and the Retrovirus Study Croup of the French Society of Blood Transfusion. Increasing diversity of HIV-1M serotypes in French blood donors over a 10-year period (1985-1995). AIDS 1997, 11:1503-1508.
9. 9. Schockmel GA, Yerly S, Perrin L. Detection of low HIV-1 RNA levels in plasma. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 17:179-183.
10. 10. Lafeuillade A, Poggi C, Tamalet C, Profizi N. Human immunodeficiency virus type 1 dynamics in different lymphoid tissue compartments. J Infect Dis 1997, 176:804-806.
11. 11. Izopet J, Tamalet C, Pasquier C, et al. Quantification of HIV-1 proviral DNA by a standardized colorimetric PCR-based assay. J Med Virol 1998, 54:34-59.
12. 12. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995, 269:696-699.
13. 13. Wong JK, Hezareh M, Günthard HF et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viraemia. Science 1997, 278:1291-1295.
14. 14. Asjo B, Cefai D, Debre P, Dudoit Y, Autran B. A novel mode of human immunodeficiency virus type 1 (HIV-1) activation: ligation of CD28 alone induces HIV-1 replication in naturally infected lymphocytes. J Virol 1993, 67:4395-4398.
15. 15. Pantaleo G. How immune-based interventions can change HIV therapy. Nat Med 1997, 3:483-486.
16. 16. Carpenter C, Fishl MA, Hammer SM et al. Antiretroviral therapy for HIV infection in 1998. Updated recommendations of the International AIDS Society - USA panel. JAMA 1998, 280:78-86.
17. 17. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
18. 18. Mellors JW, Kingsley LA, Rinaldo CR Jr, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995, 122:573-579.
19. 19. Ho DD. Time to hit HIV, early and hard. N Engl J Med 1995, 333:450-451.
20. 20. Staszewski S, Morales-Ramirez J, Tashima K et al. A phase III, multicentre, randomized, open label study to compare the antiretroviral activity and tolerability of efavirenz (EFV) + indinavir (IDV), vs EFV + zidovudine (ZDV) + lamivudine (3TC), vs IDV + ZDV + 3TC at 36 weeks [abstract OP 5.1]. Abstracts of the Fourth International Congress on Drug Therapy in HIV Infection, Glasgow. AIDS 1998, 12(Suppl. 4):S13.
21. 21. Finzi D, Hermankova M, Pierson T et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-1300.
22. 22. Chun TW, Engel D, Berrey MM, et al. Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection. Proc Natl Acad Sci, USA 1998, 95:8869-8873.
23. 23. Pantaleo G, Soudeyns H, Demarest JF et al. Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection. Proc Natl Acad Sci, USA 1997 94:9848-9853.
24. 24. Dalod M, Harzic M, Pellegrin M et al. Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy. J Infect Dis 1998, 178:61-69.
25. 25. Rosenberg FS, Billingsley JM, Caliendo AM et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997, 278:1447-1450.
26. 26. Ho DD. Toward HIV eradication or remission: the tasks ahead. Science 1998, 280:1866-1867.
27. 27. Perrin L, Yerly S, Marchal F, et al. Virus burden in lymph nodes and blood of subjects with primary human immunodeficiency virus type 1 on bitherapy. J Infect Dis 1998, 177:1497-1501.
28. 28. Sanchez G, Xu X, Chermann JC, Hirsch I. Accumulation of defective viral genomes in peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected individuals. J Virol 1997, 71:2233-2240.
29. 29. Orenstein JM, Fox C, Wahl SM. Macrophages as a source of HIV during opportunistic infections. Science 1997, 276:1857-1861.
30. 30. Fauci AS. Host factors in the pathogenesis of HIV disease: role of cellular activation and cell signaling]. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago 1998 [abstract 543].